



# Acknowledgments

*Praise to "Allah", the Most Gracious and the Most Merciful Who Guides Us to the Right Way.*


*I would like to express my endless gratitude and appreciation to Prof. Dr. Tarek Mostafa Kamal El Weseily, Professor of Pediatrics, Faculty of medicine, University of Alexandria for giving me the honor of working under his supervision and providing me with a lot of encouragement and support.*

*My special thanks and deep gratitude to Prof. Dr. Akram Abd Almoneim Deghady, Professor of Clinical and Chemical Pathology, Faculty of medicine, University of Alexandria, for his generous assistance and valuable guidance and unfailing efforts during the whole period of the study.*

*This work would have never been completed without the great help, close supervision offered by Prof. Dr. Mohamed Hazem Gouda, Professor of Pediatrics, Faculty of medicine, University of Alexandria.*

*A due thanks are extended to Dr. Ali Mohamed Abd Almohsen, Assistant Professor of Pediatrics, Faculty of Medicine, University of Alexandria, for his kind help and remarks.*

*Last but not least, I owe special thanks and gratitude to my family who nurtured, loved and faithfully supported me throughout this entire work.*



# TABLE OF CONTENTS

| <b>Chapter</b>                                   | <b>Page</b> |
|--|-------------|
| <b>ACKNOWLEDGMENTS</b> .....                     | <b>i</b>    |
| <b>TABLE OF CONTENT</b> .....                    | <b>ii</b>   |
| <b>LIST OF TABLES</b> .....                      | <b>iii</b>  |
| <b>LIST OF FIGURES</b> .....                     | <b>iv</b>   |
| <b>LIST OF ABBREVIATIONS</b> .....               | <b>v</b>    |
| <b>I. INTRODUCTION</b> .....                     | <b>1</b>    |
| <b>II. AIM OF THE WORK</b> .....                 | <b>7</b>    |
| <b>III. SUBJECTS</b> .....                       | <b>8</b>    |
| <b>IV. METHODS</b> .....                         | <b>9</b>    |
| <b>V. RESULTS</b> .....                          | <b>12</b>   |
| <b>VI. DISCUSSION</b> .....                      | <b>22</b>   |
| <b>VII. SUMMARY</b> .....                        | <b>25</b>   |
| <b>VIII. CONCLUSION AND RECOMMENDATION</b> ..... | <b>27</b>   |
| <b>IX. REFERENCES</b> .....                      | <b>28</b>   |
| <b>PROTOCOL</b>                                  |             |
| <b>ARABIC SUMMARY</b>                            |             |

## LIST OF TABLES

| <b>Table</b>   | <b>Page</b> |
|--|-------------|
| 1. studied subgroups A1, B1 and C1 according to demographic data ----- | 12          |
| 2. studied subgroups A2, B2 and C2 according to demographic data ----- | 12          |
| 3. studied groups according to diagnosis -----                         | 13          |
| 4. studied subgroups A1, B1 and C1 according to eGFR -----             | 13          |
| 5. studied subgroups A2, B2 and C2 according to eGFR -----             | 14          |
| 6. studied subgroups A1, B1 and C1 according to U Alb/Cr -----         | 15          |
| 7. studied subgroups A2, B2 and C2 according to U Alb/Cr -----         | 16          |
| 8. studied subgroups A1, B1 and C1 according to U NAG/Cr -----         | 17          |
| 9. studied subgroups A2, B2 and C2 according to U NAG/Cr -----         | 18          |
| 10. studied subgroups A1, B1 and C1 according to serum B2M -----       | 19          |
| 11. studied subgroups A2, B2 and C2 according to serum B2M -----       | 20          |

# LIST OF FIGURES

| <b>Figure</b>  | <b>Page</b> |
|--|-------------|
| 1. Time course of total congenital heart disease birth prevalence from 1930 until 2010 ----- | 2           |
| 2. studied subgroups A1, B1 and C1 according to eGFR -----                                   | 14          |
| 3. studied subgroups A2, B2 and C2 according to eGFR -----                                   | 15          |
| 4. studied subgroups A1, B1 and C1 according to U Alb/Cr -----                               | 16          |
| 5. studied subgroups A2, B2 and C2 according to U Alb/Cr -----                               | 17          |
| 6. studied subgroups A1, B1 and C1 according to U NAG/Cr -----                               | 18          |
| 7. studied subgroups A2, B2 and C2 according to U NAG/Cr -----                               | 19          |
| 8. studied subgroups A1, B1 and C1 according to serum B2M -----                              | 20          |
| 9. studied subgroups A2, B2 and C2 according to serum B2M -----                              | 21          |

## LIST OF ABBREVIATIONS

|                                      |   |   |
|--------------------------------------|---|---|
| <b>CHD</b>                           | : | Congenital heart disease                              |
| <b>VSD</b>                           | : | Ventricular septal defect                             |
| <b>ASD</b>                           | : | Atrial septal defect                                  |
| <b>CCHD</b>                          | : | Cyanotic congenital heart disease                     |
| <b>ECA</b>                           | : | Extracardiac anomaly                                  |
| <b>PAH</b>                           | : | Pulmonary arterial hypertension                       |
| <b>CVA</b>                           | : | Cerebrovascular accident                              |
| <b>CKD</b>                           | : | Chronic kidney disease                                |
| <b>GFR</b>                           | : | Glomerular filtration rate                            |
| <b>β<sub>2</sub>M</b>                | : | β <sub>2</sub> -microglobulin                         |
| <b>NAG</b>                           | : | N-acetyl-β-D-glucosaminidase                          |
| <b>AKI</b>                           | : | Acute kidney injury                                   |
| <b>NGAL</b>                          | : | neutrophil-gelatinase-associated lipocalin            |
| <b>eGFR</b>                          | : | estimated glomerular filtration rate                  |
| <b><math>\frac{U}{Alb/Cr}</math></b> | : | Urinary Albumin creatinine ratio                      |
| <b><math>\frac{U}{NAG/Cr}</math></b> | : | Urinary N-acetyl-β-D-glucosaminidase creatinine ratio |